LATHAM, N.Y. / Jul 29, 2024 / Business Wire / AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that its management is scheduled to participate in the following upcoming investor conferences:
9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
Date: August 12, 2024
Canaccord Genuity 44th Annual Growth Conference
Presentation: August 13, 2024 at 10:00am
A live webcast of the presentation will be accessible through the “Investors” section of the Company’s website at www.angiodynamics.com.
About AngioDynamics, Inc.
AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.
The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.
| Last Trade: | US$8.73 |
| Daily Change: | -0.33 -3.64 |
| Daily Volume: | 423,799 |
| Market Cap: | US$354.700M |
July 28, 2025 July 23, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
